Language Select
Varian Logo
Varian-Equipped St. Petersburg Proton Therapy Center Completes First Patient Treatment
March 20, 2018

PALO ALTO, Calif., March 20, 2018 /PRNewswire/ -- Varian (NYSE: VAR) announced PTC St. Petersburg Center of Nuclear Medicine of the Sergey Berezin Medical Institute successfully completed its first pediatric patient treatment with the Varian ProBeam® proton therapy system. The patient was treated for a brain tumor at Russia's first dedicated proton therapy treatment center.

The two-treatment room PTC St. Petersburg Center of Nuclear Medicine of the Sergey Berezin Medical Institute offers image-guided intensity modulated proton therapy (IMPT) with a ProBeam system. Clinicians at the center expect to treat approximately 1,000 patients each year.

"There are large groups of patients in Russia, especially children, with different kinds of tumors who will benefit from our project," said Dr. Arkadi Stolpner, president of the Sergey Berezin Medical Institute. "With this installation, we are taking a huge step forward in increasing the treatment capacity in Russia. Proton therapy with ProBeam is an efficient treatment method and there is a great need for this unique technology." 

Varian's ProBeam system is the first to offer fully-integrated IMPT to enable more efficient adaptive proton therapy. Varian's pencil-beam scanning technology gives clinicians the ability to deliver the dose precisely within the contours of the tumor to minimize dose to healthy tissue. When combined with integrated cone-beam computed tomography (CBCT), the ProBeam system enables advanced adaptive therapy during the course of treatment, helping to make it a more precise form of proton therapy.

"We are proud of our collaboration with the St. Petersburg Proton Therapy Center and bringing this advanced cancer treatment technology to patients in Russia," said Dr. Moataz Karmalawy, general manager of Varian's Particle Therapy division. "This is a major step forward in the global fight against cancer."

About Varian
Varian is a leader in developing and delivering cancer care solutions, and is focused on creating a world without fear of cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit and follow @VarianMedSys on Twitter.

Press Contact
Mark Plungy
Director, Public Relations
+1 (650) 424-5630

Investor Relations Contact
J. Michael Bruff
Senior Vice President, Investor Relations
+1 (650) 424-5163